- Home
- ANAB vs SIND Comparison
ANAB vs SIND Comparison
Compare ANAB & SIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANAB | SIND |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.9B |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANAB | SIND |
|---|---|---|
| Price | $54.57 | $14.38 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $71.67 | N/A |
| AVG Volume (30 Days) | ★ 723.1K | 109.6K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $234,603,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $52.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 157.01 | N/A |
| 52 Week Low | $17.11 | $10.03 |
| 52 Week High | $73.30 | $15.00 |
Technical Indicators
Market Signals| Indicator | ANAB | SIND |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 62.21 |
| Support Level | $54.23 | $11.15 |
| Resistance Level | $57.70 | $14.99 |
| Average True Range (ATR) | 3.31 | 1.63 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 57.04 | 89.13 |
Price Performance
Historical ComparisonAbout ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About SIND Sinda Ltd.
Sinda Ltd is an exploration stage company focused on acquiring, exploring, and developing mineral concessions in Mexico. The company holds mining concessions and exploration and exploitation rights for a silver-gold project located in the Guanajuato silver belt of Mexico. Its principal asset is the Sinda Property, a silver project at the exploration stage.